论文部分内容阅读
采用酶联免疫吸附试验（ＥＬＩＳＡ）检测８４例肝癌病人和８０例非肝癌病人血清中的戊型肝炎抗体（抗－ＨＥＶ）、丙型肝炎抗体（抗－ＨＣＶ）和乙肝表面抗原（ＨＢｓＡｇ）。结果：两种人群相应抗体抗原的阳性率依次为：１０．７％、３０．０％、８０．１％和５．０％、５．０％、１０．０％，两组比较，相应阳性率的Ｐ值分别为Ｐ＞０．０５，Ｐ＜０．０１，Ｐ＜０．０１，ＯＲ值分别为１．１、６、８。认为：肝癌病人存在着ＨＥＶ感染；肝癌发生仍以ＨＢＶ感染关系最密切，次为ＨＣＶ感染，与ＨＥＶ感染关系不大。
Enzyme-linked immunosorbent assay (ELISA) was used to detect hepatitis E antibody (anti-HEV), hepatitis C antibody (anti-HCV) and hepatitis B surface antigen (HBsAg) in sera of 84 patients with hepatocellular carcinoma and 80 patients without hepatocellular carcinoma. Results: The positive rates of the corresponding antibody antigens in the two populations were 10.7%, 30.0%, 80.1% and 5.0%, 5.0% and 10.0% respectively. In the two groups, the corresponding positive rates Rate of P values were P> 0.05, P <0.01, P <0.01, OR values were 1.1,6,8. It is considered that there is HEV infection in patients with liver cancer, HBV infection is most closely related to occurrence of liver cancer, and HCV infection is secondary, which has little to do with HEV infection.